Sedivention, a Straßlach, Germany-based medical technology startup, received €800K in Pre-Seed funding.
The round was led by High-Tech Gründerfonds (HTGF).
The company intends to use the funds to advance the first preclinical studies and product development.
Led by Dr. Ute Nollert and Dr. Andreas Bröcker, Sedivention is developing a medical device that enables a one-time, interventional, and minimally invasive therapy for obesity. The company is developing a cryocatheter that ablates the gastric branches of the vagus nerve within minutes. The procedure can be performed in an outpatient setting, similar to a gastroscopy, as a one-time, minimally invasive procedure.
A prototype has already been developed and successfully tested for safety and efficacy. Sedivention will use the capital raised to advance product development and preclinical testing.
FinSMEs
18/11/2024